<DOC>
	<DOCNO>NCT00399594</DOCNO>
	<brief_summary>Identifying &amp; optimize strategy reduce burden heart failure vital . Despite advance pharmacotherapy , patient heart failure high risk death &amp; hospitalization . Cardiac resynchronization therapy ( CRT ) synchronize ventricular mechanical activity , improve cardiac output &amp; reduces HF symptom . However , ~50 % patient clearly respond CRT . Sub-optimal placement LV pace lead appear important reason non-response . This study ass whether targeted LV lead placement result increase probability CRT response 52 week vs. usual ( lateral wall ) lead placement .</brief_summary>
	<brief_title>Effect Targeting Left Ventricular Lead Position Rate Response Cardiac Resynchronization Therapy .</brief_title>
	<detailed_description>Background . Identifying &amp; optimize strategy reduce burden heart failure ( HF ) vital . Despite advance pharmacotherapy , patient HF high risk death &amp; hospitalization . Over 25 % patient systolic HF dyssynchronous ventricular contraction result paradoxical septal motion , impair leave ventricular ( LV ) function &amp; HF progression . Cardiac resynchronization therapy ( CRT ) synchronize ventricular mechanical activity , improve cardiac output &amp; reduces HF symptom . However , ~50 % patient clearly respond CRT . Sub-optimal placement LV pace lead appear important reason non-response . Screening . Mechanical synchrony vitally important optimize CRT response . Patients pre-screened echocardiogram ( echo ) &amp; CRT provide dyssynchrony . The predicted rate CRT response patient pre-screened dyssynchrony estimate 65 % . CRT response . The combined use valid &amp; simple measure functional capacity reproducible measure LV volume optimal identify CRT responder . These outcome assess use Specific Activity Scale &amp; radionuclide angiography ( RNA ) , respectively . Primary hypothesis . Targeted LV lead placement result increase probability CRT response 52 week vs. usual ( lateral wall ) lead placement . CRT response define ≥ 10 % relative reduction LV end systolic volume &amp; ≥ 1 Specific Activity Scale class improvement .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>LV EF ≤ 0.40 measure within 3 month enrollment , SAS class 3 4 symptom indicative moderate severe functional capacity limitation due heart failure within 1 month enrollment . Confirmed dyssynchrony screen echo ( 1.1.9 ) , &amp; On stable dos ACE inhibitor angiotensin II blocker &amp; betablocker ≥ 2 month unless medically contraindicate . Controlled heart rate permanent AF ( rest &lt; 70 &amp; maximal &lt; 120 ) . Unable unwilling provide inform consent , Medical condition heart failure likely cause death &lt; 1 year , Cardiac transplant plan within 6 month , Known contraindication transvenous CRT device implant ( e.g. , active sepsis , artificial tricuspid valve , know vascular occlusion prevent delivery lead transvenously ) , Clinically significant myocardial infarction within last 2 month , Coronary bypass graft surgery ≤ 2 month coronary angioplasty ≤ 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Mechanical dyssynchrony</keyword>
	<keyword>Biventricular pacing</keyword>
	<keyword>Cardiac resynchronization therapy</keyword>
</DOC>